Search research articles
Contact Us
Filters
Showing results (531-540 of 700) with videos related to
Page
of 70
Sort By:
Cancer Chemotherapy and Pharmacology
|
January 1, 1997
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin
G F Fleming, S M O'Brien, P C Hoffman, et al.
Journal of Vocational Rehabilitation
|
October 11, 2016
Virtual Reality Job Interview Training for Veterans with Posttraumatic Stress Disorder
Matthew J Smith, Laura Boteler Humm, Michael F Fleming, et al.
Cancer
|
September 27, 2006
Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study
G Larry Maxwell, Chunqiao Tian, John Risinger, et al.
Family Medicine
|
May 1, 1992
Creating a substance abuse network in family medicine: lessons learned
A K Davis, A V Graham, P G Coggan, et al.
Biorxiv : the Preprint Server for Biology
|
February 20, 2025
Updated Guidance for Communicating PFAS Identification Confidence with Ion Mobility Spectrometry
Anna K Boatman, Jessie R Chappel, Kaylie I Kirkwood-Donelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2003
Phase I study of an oral formulation of ZD9331 administered daily for 28 days
Michael B Sawyer, Mark J Ratain, Donna Bertucci, et al.
Gynecologic Oncology
|
January 21, 2018
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
Heidi J Gray, Katherine Bell-McGuinn, Gini F Fleming, et al.
Environmental Science & Technology
|
August 14, 2025
Updated Guidance for Communicating PFAS Identification Confidence with Ion Mobility Spectrometry
Anna K Boatman, Jessie R Chappel, Kaylie I Kirkwood-Donelson, et al.
Cancer Chemotherapy and Pharmacology
|
April 1, 1999
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days
M D DeMario, M J Ratain, N J Vogelzang, et al.
Cureus
|
November 2, 2022
An Assessment of Risk Factors of Delayed Speech and Language in Children: A Cross-Sectional Study
Anish Kumar, Maryam Zubair, Azouba Gulraiz, et al.
Page
of 70
Search research articles
Search
Showing results (531-540 of 700) with videos related to
Sort By:
Page
of 70
Cancer Chemotherapy and Pharmacology
|
January 1, 1997
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin
G F Fleming, S M O'Brien, P C Hoffman, et al.
Journal of Vocational Rehabilitation
|
October 11, 2016
Virtual Reality Job Interview Training for Veterans with Posttraumatic Stress Disorder
Matthew J Smith, Laura Boteler Humm, Michael F Fleming, et al.
Cancer
|
September 27, 2006
Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study
G Larry Maxwell, Chunqiao Tian, John Risinger, et al.
Family Medicine
|
May 1, 1992
Creating a substance abuse network in family medicine: lessons learned
A K Davis, A V Graham, P G Coggan, et al.
Biorxiv : the Preprint Server for Biology
|
February 20, 2025
Updated Guidance for Communicating PFAS Identification Confidence with Ion Mobility Spectrometry
Anna K Boatman, Jessie R Chappel, Kaylie I Kirkwood-Donelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2003
Phase I study of an oral formulation of ZD9331 administered daily for 28 days
Michael B Sawyer, Mark J Ratain, Donna Bertucci, et al.
Gynecologic Oncology
|
January 21, 2018
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
Heidi J Gray, Katherine Bell-McGuinn, Gini F Fleming, et al.
Environmental Science & Technology
|
August 14, 2025
Updated Guidance for Communicating PFAS Identification Confidence with Ion Mobility Spectrometry
Anna K Boatman, Jessie R Chappel, Kaylie I Kirkwood-Donelson, et al.
Cancer Chemotherapy and Pharmacology
|
April 1, 1999
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days
M D DeMario, M J Ratain, N J Vogelzang, et al.
Cureus
|
November 2, 2022
An Assessment of Risk Factors of Delayed Speech and Language in Children: A Cross-Sectional Study
Anish Kumar, Maryam Zubair, Azouba Gulraiz, et al.
Page
of 70